Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess the Efficacy, Safety and Tolerability of AKB-9778 Ophthalmic Solution as and Adjunct to Latanoprost in Patients With Ocular Hypertension or Open Angle Glaucoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~* Diagnosis of OAG or OHT in each eye (OAG in one eye and OHT in the fellow eye is acceptable)~* Must be receiving treatment with a stable regimen of topical prostaglandin eyedrop for a minimum of 2 weeks prior to the Screening Visit; may be taking one additional IOP lowering eyedrop~* IOP of ≥ 18 mmHg and ≤ 27 mmHg in one eye or both eyes at Screening visit~* Following 4 week washout period, IOP ≥ 24 mmHg and \< 36 mmHg at 08:00 hour and IOP ≥ 22 mmHg and \< 36 mmHg in both eyes at 10:00, 12:00 and 16:00 hours.~Key Exclusion Criteria:~* Clinically significant ocular disease which might interfere with interpretation of the study efficacy endpoints or with safety assessments~* Pseudoexfoliation or pigment dispersion component glaucoma~* History of angle closure glaucoma, or narrow angles or with evidence of peripheral anterior synechiae (PAS) ≥ 180 degrees by gonioscopy within 6 months prior to Screening~* Intraocular pressure ≥ 36 mmHg~* Cup/disc ratio of \> 0.8 in either eye~* Severe visual field defect or significant defect (sensitivity of ≤ 10dB) within 10 degrees of fixation in either eye

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AKB-9778 4% QD + Latanoprost (Type: EXPERIMENTAL): • AKB-9778 4% daily (AM) and placebo for ophthalmic solution daily (PM) plus latanoprost daily (PM) for 28 days
- AKB-9778 4% BID + Latanoprost (Type: EXPERIMENTAL): • AKB-9778 4% twice daily (AM \& PM) plus latanoprost daily (PM) for 28 days
- Placebo Twice Daily + Latanoprost (Type: PLACEBO_COMPARATOR): • Placebo for AKB-9778 4% ophthalmic solution twice daily (AM \& PM) plus latanoprost daily (PM) for 28 days

Based on this trial design, predict the completion outcome and termination type (if applicable).